Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
Status:
Not yet recruiting
Trial end date:
2028-10-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety,
tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in
participants with advanced or metastatic solid tumors administered as a monotherapy and in
combination with pembrolizumab.